-
On March 25, 2025 the U.S. Food and Drug Administration (FDA) issued a warning letter to the sponsor-investigator of a study due to objectionable conditions observed during a Bioresearch Monitoring (BIMO) Program inspection. The sponsor-investigator’s written response to the FDA Form 483 were deemed inadequate therefore the FDA issued a warning letter stating that the sponsor-investigator was noncompliant with multiple regulations within 21 CFR part 312.
-
On April 30th, 2025, the U.S. Food and Drug Administration (FDA) issued a warning letter and Form FDA 483 to the sponsor of a clinical investigation as the result of a Bioresearch Monitoring Program (BIMO) inspection. 40 participants were enrolled in the study and took the investigational product that the sponsor claims was to help individuals with sleeping disorders without submitting an Investigational New Drug (IND) application.
-
On January 31st, 2025, the European Medicines Agency (EMA) reached another major milestone for the implementation of the Clinical Trials Regulation (CTR), the European Union’s (EU) current pharmaceutical legislation. The CTR has updated the many of the CTD policies; promoting communication between trials and regulators, increased transparency between trials and the public, and reducing financial and administrative burdens.
-
On April 4th, 2025, the U.S. Food and Drug Administration (FDA) updated their Institutional Review Board (IRB) Guidance Manual, part of the Bioresearch Monitoring (BIMO) Compliance Program. Staying up to date with these sorts of regulatory updates will help better prepare for inspections and give IRBs a chance to update any relevant protocols or policies that may not be compliant with these new changes.
-
On June 17th, 2025, the U.S. Food and Drug Administration (FDA) introduced its Commissioner’s National Priority Voucher (CNVP) pilot program to accelerate development of select drugs or biologics from companies that are supporting U.S. national interests and are aligned with U.S. national health priorities.
Date: April 20, 2017
Time: 11:00 am EST | 15:00 GMT
Join us and CRF Health on this upcoming webinar hosted by Xtalks. We'll discuss the following benchmarks from the State of eConsent 2017 Report: https://attendee.gotowebinar.com/register/5600985180645861634
“Q: If local policy differs from the region’s regulations pertaining to the conduct of a clinical trial at a research site, what should be followed? A: The strictest requirements”. In response to this question one may ask, where can I find the local regulations for my study? A situation compounded in multinational trials. A helpful tool to reference is the OHRP’s International Compilation of Human Research Standards which was first published on 2005.
Time: 12-1 pm
To Sign-up: Link to ACRP eConsent Webinar
Registration Deadline: February 27, 2017
Description:
In this webinar Sandra “SAM” Sather, VP, Clinical Pathways, Regulatory & Quality lead for eConsent, CRF Health Trial Consent and Michael Conde, is the Senior Director of Technical Solutions at CRF Health discuss how eConsent (eIC) improves investigator, sponsor and IRB oversight for informed consent and decreases risks.
Part 2 of this series summarized the background and need for the upcoming updates to ICH E6 and ICH E8 per the ICH’s reflection paper that is currently available here and is open to stakeholder comment until March 27th. Section 2 of the reflection paper “Proposed Structure for a Modernized ICH E8 Guideline and a Future Renovated ICH E6 Guideline” focuses on ICH E8 explaining the need for modernization.
